| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Alpha Cognition (NASDAQ:ACOG) reported quarterly sales of $2.300 million which beat the analyst consensus estimate of $2.033 mi...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Alpha Cognition (NASDAQ:ACOG) with a Buy and lowers the price t...
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical c...
Alpha Cognition Inc. (NASDAQ:ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative dis...
Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareh...
Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developin...
- SEC Filing